Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

Prader-Willi syndrome (PWS) is characterized by lack of appetite control and hyperphagia, leading to obesity.

Who Took Part

PubMed indexes the participants as children and teenagers.

Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included.

All patients followed a structured diet and exercise program throughout the trial.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

Running at several centres spread the Liraglutide study over different clinics and patient groups.

A time span of 52 weeks appears in the methods.

This was a multicenter, 52-week, placebo-controlled trial with a 16-week double-blinded period.

Liraglutide was continued for 52 weeks.

The coprimary endpoints were change in body mass index (BMI) standard deviation score (SDS) from baseline to 16 and 52 weeks.

Secondary endpoints included other weight-related parameters, hyperphagia, and safety.

What Was Measured

PubMed files the paper under topics including Liraglutide, Prader-Willi Syndrome, Obesity, Hyperphagia and Body Mass Index.

The authors tagged it with the keywords BMI SDS, Prader–Willi Syndrome, adolescents, children and pediatric population.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide over 52 weeks.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Liraglutide compound page.